Latest Conference Articles

An analysis of over 2.5 million patients with type 2 diabetes shows newer GLP-1 RAs are linked to lower HbA1c levels.

Halis Akturk, MD, offers an overview of the growing prevalence and dangers associated with cannabis use among patients with type 1 diabetes.

Use of LX9211 showed significant benefits for diabetic peripheral neuropathic pain in the phase 2 RELIEF-DPN 1 trial.

Details of an analysis from ADA 2024 compared matched cohorts from SURMOUNT-1 and SURMOUNT-2 to determine drivers of differences in weight loss from the trials.

Omnipod 5 improved HbA1c from 8.2% to 7.4% in 13 weeks among adults with type 2 diabetes in the SECURE-T2D trial, with a nearly 5-hour increase in time in range per day.

ADA study highlights disparities in CGM access for children with type 1 diabetes, showing delays for publicly insured and minority children.

New data from INHALE-3 at ADA 84th Scientific Sessions show inhaled insulin (Afrezza) is safe, effective for type 1 diabetes, improving glycemic control and HbA1c goals.

Participants assigned to a 4-day energy balance diet plus oral bisphenol A administration at 50 μg/kg body weight experienced significant decreases in peripheral insulin sensitivity.

In retrospective, observational research at ADA 2024, real-world weight loss was linked to a reduction in the risk of obesity-related cancers.

New phase 1/2 data suggest VX-880 islet cell therapy may restore physiological islet function and glycemic control in patients with T1D, potentially eliminating the need for insulin use.

Tirzepatide reduces OSA severity by 30 events/hour and achieves remission in up to 51% of patients with obesity, per SURMOUNT-OSA study results from Eli Lilly and Company.

A first-time trial presented at ADA 2024 found the common cholesterol-lowering drug halts vision loss in patients with diabetic eye disease.

These data, presented at RAD 2024, highlight the potential of delgocitinib cream for patients with chronic hand eczema in terms of patient and clinician reported outcomes.

Patients in the spesolimab cohort demonstrated rapid improvements in DLQI scores compared with placebo, which were maintained through week 48.

These data highlighted which drug, in combination with topical corticosteroids, produced the best efficacy results for those with atopic dermatitis.

Matthew Zirwas, MD, reviews the clinical discrepancies of certain JAK-targeting therapies and their role in dermatology patient outcomes.

Matthew Zirwas, MD, discusses the prospect of pairing JAK inhibitors like ruxolitinib cream with other disease-targeting options for conditions including vitiligo and alopecia areata.

These data, presented at RAD 2024, highlight the potential benefits of upadacitinib for adults and adolescents observed in the Measure Up 1 and Measure Up 2 studies.

Responses were highly durable throughout 4 years of bimekizumab treatment.

Jennifer L. Hsiao, MD, reviews the rapidly growing inventory of investigational drugs for HS.

Matthew Zirwas, MD, explains why he believes agents like ruxolitinib cream and upadacitinib have become the optimal treatments for atopic dermatitis, hidradenitis suppurativa, and more.

Significantly greater improvements were reported at week 2, which were sustained through week 12, in patients receiving the halobetasol propionate/tazarotene lotion compared with the vehicle cohort.

Sidbury covered the similarities and differences between the new guideline updates by the AAD on atopic dermatitis as well as differences with other organizations’ guidelines.

In new late-breaking data, alopecia patients’ real-world incidence of atopic dermatitis was highlighted by investigators.

Overall, 189 (74.1%) patients treated with brodalumab achieved PASI 75, 133 (52.2%) achieved PASI 90, and 98 (38.4%) achieved PASI 100.

Bourjeily told HCPLive at SLEEP 2024 that sleep issues, such as insomnia and restless legs syndrome, are the most common during the first and third trimester of pregnancy.

These data presented at RAD 2024 highlight the differences among eczema patient preferences in terms of administration modes, risk levels, and more.

The first line treatment for restless legs syndrome—dopamine agonists—may be making a patient’s condition worse in the long-term, Winkelman told HCPLive at SLEEP 2024.